Latham & Watkins Advises the Underwriters in Twist Bioscience’s Upsized Public Offering

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, has announced the pricing of an upsized, underwritten public offering of 4,545,454 shares of its common stock at a price to the public of US$55 per share. The gross proceeds of the offering to Twist before deducting the underwriting discount and commissions and estimated offering expenses, and assuming no exercise of the underwriters’ option to purchase additional shares from the Company, will be approximately US$250 million. Twist has granted the underwriters a 30-day option to purchase up to an additional 681,818 shares of common stock at the public offering price, less the underwriting discount and commissions. The offering is expected to close on or about February 15, 2022, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by Bay Area partners Brian Cuneo and Phillip Stoup, with Orange County associate Eric Hanzich, Bay Area associate Casey Tong and Orange County associate AJ Blair. Advice was also provided on tax matters by Bay Area partner Grace Lee, with Bay Area associate Derek Gumm; and on intellectual property matters by Bay Area partner Christopher Hazuka, with San Diego associate Robert Yeh and Los Angeles associate Michael Sweeney.